DiaMedica Inc. Announces Results of Annual and Special General Meeting
September 23 2011 - 3:05PM
Marketwired
DiaMedica Inc. ("DiaMedica") (TSX VENTURE: DMA), a biotechnology
company focused on diabetes, is pleased to announce that at the
Annual and Special General Meeting (the "AGM") of shareholders of
DiaMedica dated September 22, 2011 David Allan, Michael Giuffre,
Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas Wellner were
elected as the board of directors of the Corporation.
In addition to the election of directors, the shareholders
passed all resolutions placed before them as outlined in the
management information circular dated August 25, 2011, including
the re-appointment of KPMG LLP, Chartered Accounts, as auditors for
the upcoming year, the adoption of a shareholder rights plan, the
adoption of an amended and restated stock option plan, and the
adoption of a deferred share unit plan.
About DiaMedica
DiaMedica is a biopharmaceutical company that has developed
novel therapeutic compounds aimed to improve the lives of patients
with diabetes and other major, medically unmet diseases.
DiaMedica's lead compound, DM-199, represents a novel approach to
treating Type 1 and Type 2 diabetes by demonstrating significant
results against three major aspects of these diseases: 1) halting
the autoimmune attack on beta cells; 2) proliferating insulin
producing beta cells and 3) improving glucose control.
DiaMedica is also developing DM-204, a monoclonal antibody that
inhibits the enzyme glycogen synthase kinase. In preclinical
studies, DM-204 significantly improved glucose control and
decreased blood pressure.
The Company is listed on the TSX Venture Exchange under the
trading symbol 'DMA'.
FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not
historical facts contain forward-looking information that involves
risk and uncertainties. All statements, other than statements of
historical facts, which address DiaMedica's expectations, should be
considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions
made by and information currently available to management. When
used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar
import, are intended to identify any forward-looking statements.
You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as
contained in the Company's filings with Canadian securities
regulatory authorities. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company
undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of any unanticipated events.
Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of the contents of this News Release.
Contacts: DiaMedica Inc. Rick Pauls President and CEO
204.477.7590 rpauls@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024